Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Ono Fires Back to 1.75 Trillion Yen Guesstimate, Puts Opdivo Sales at 126 Billion Yen
Ono Pharmaceutical on April 11 moved to rebut an emerging speculation that its immuno-oncology drug Opdivo (nivolumab) could cost 1.75 trillion yen for its lung cancer indication by unveiling its own sales forecast a month ahead of schedule. In the…
To read the full story
Related Article
- Ono Delivers Record Sales on Buoyant Opdivo, FY2016 Outlook Tops 250 Billion Yen
May 12, 2016
- Front-Loaded Price Cuts Necessary for Drugs Like Opdivo: JMA’s Nakagawa
April 7, 2016
- MOF Panel Hears Expert’s Opinions on Opdivo Prices
April 5, 2016
- Pricing Debate Spills Over into MHLW Safety Panel, Member Warns Opdivo Costs Could Jeopardize State Finances
February 22, 2016
BUSINESS
- Merck Biopharma Starts Japan PIII Trial of LH/FSH Combo
July 17, 2026
- Eisai’s Dayvigo Accepted for EMA Review
July 17, 2026
- AbbVie Files Maviret for Acute Hepatitis C
July 17, 2026
- FRONTEO, Santen Advance AI Drug Discovery Project to Second Phase
July 17, 2026
- Ferring’s Adstiladrin, Boehringer’s Jascayd Hit Market; Haizexin Due July 28
July 16, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…